



## Effect of Renal Complications on Brain - An Overview

**Shalini K Mehta<sup>1</sup> and Sivakumar JT Gowder<sup>2\*</sup>**<sup>1</sup>RL Abhishek Rao College of Pharmacy, Kalyana Nagar, Bangalore, India<sup>2</sup>Department of Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Vietnam**\*Corresponding Author:** Sivakumar JT Gowder, Department of Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Vietnam**Received:** February 08, 2020**Published:** March 20, 2020© All rights are reserved by **Shalini K Mehta and Sivakumar JT Gowder.**

The association between chronic kidney disease (CKD) and cardiovascular disease has been extensively studied but, at the same time, little information has been available on the relationship between kidney and brain. In this manuscript, we have evaluated the recent updates on the relation between CKD and neurological disorders based on literature review and survey. A wide spectrum of neurological disturbances and behavioral changes such as fatigue, head ache, sensory clouding, vision impairment, seizures, delirium and coma can be observed in patients with renal complications [1-4].

One of the major problems arising due to renal failures is uremic encephalopathy. Uremic encephalopathy may occur in patients with either acute or chronic renal failure when the glomerular filtration rate falls below approximately 10% of normal. The severity of uremic encephalopathy is often dependent on the type of renal failure. In CKD, the symptoms are usually mild. The patient shows impaired concentration and behavioral changes; these symptoms are however not specific to encephalopathy, and are often associated with other diseases; major depressive disorder, hypertensive encephalopathy, or caused by drug side-effects, as a result, correct diagnosis is rarely possible. In acute renal diseases, the symptoms are more pronounced and more progressive. The severity of uremic encephalopathy correlates with the extent and kinetics of the accumulation of uremic toxins [5,6].

Experiments conducted on uremic animals have shown disturbances of the intermediary metabolism with increased levels of creatine phosphate, adenosine triphosphate and glucose; and decreased levels of monophosphate, adenosine diphosphate and lactate in the brain. We can also notice the inhibition of cerebral

sodium potassium ATPase in experimental uremic animals. This results in the elevation of intracellular sodium which is responsible for cerebral dysfunction, particularly seizure activity. While the levels of certain biochemical compounds such as water, magnesium in the brain are normal; the level of calcium is found to be twice the amount. This increase in calcium levels indicates that parathyroid hormone may be involved in some way which facilitates the entry of calcium into the brain, leading to a relevant increase of calcium in the gray and white matter [3,5,6].

Studies have shown that many of the abnormalities that are found in uremic encephalopathy and calcium brain abnormalities can be reduced by parathyroidectomy; conversely these abnormalities can also be reproduced by this hormone to normal animals, while maintaining calcium and phosphate in the normal range. Thus, parathyroid hormone appears to be involved in the pathophysiology of uremic encephalopathy [6].

Dialysis encephalopathy or dialysis dementia is a progressive and often fatal disease, seen in patients of all ages but is common among children and elderly patients. In most of the cases, it leads to death in 6 months. Dialysis encephalopathy was first found by Alfred, *et al.* in the year 1972. It is believed that high levels of aluminum were the cause of dialysis dementia. Aluminum intoxication was probably first implicated in this disorder when studies showed that the aluminum content of brain gray matter in patients with dialysis encephalopathy was markedly elevated as compared with controls. The amount of aluminium in the brain was more than three times greater in patients with dialysis encephalopathy than in patients being treated with chronic hemodialysis who did not have dialysis encephalopathy [6,7].

The initial cases of dialysis encephalopathy were all of the endemic form and usually occurred in patients being treated with chronic hemodialysis for more than 2 years. The initial symptoms include dysarthria, apraxia, and slurring of speech, with stuttering and hesitancy. The patients may also have personality changes, psychosis, dementia, myoclonus, and seizures. The initial symptoms are usually intermittent and often worsen during dialysis. Treatment of dialysis dementia is usually by the chelation therapy whereas the preventive measures include usage of deionized water for the preparation of the dialysate. It has been reported that 20% of patients with chronic renal failure suffer from incapacitating disorder of restless leg syndrome. The carpal tunnel syndrome (CTS) has also been reported in CKD. It is characterized by a numbness of the volar first three fingers and hand, with paresis and atrophy of the thenar muscles [7-10].

The occurrence of subdural hematoma in the patients under hemodialysis is increased more than 20-fold when compared with the general population. Subdural hematoma and intracerebral hemorrhage and micro hemorrhages are discrete or isolated punctuate hypointense lesions smaller than 5 mm on T2\*-weighted MRI. These changes are connected with increased risk of intracranial hemorrhage and polyneuropathy [11-15].

## Bibliography

1. Mayumi K., *et al.* "Relationship between silent brain infarction and chronic kidney disease". *Nephrology Dialysis Transplantation* 24 (2009): 201-207.
2. Agildere AM., *et al.* "Evaluation of Neurologic Complications by Brain MRI in Kidney and Liver Transplant Recipients". *Transplantation Proceedings* 38 (2006): 611- 618.
3. Brouns R and De Deyn PP. "Neurological complications in renal failure: a review". *Clinical Neurology and Neurosurgery* 107 (2004): 1-16.
4. Ludwig K., *et al.* "Beneficial of renal transplantation on cognitive brain function". *Kidney International* 49 (1996): 833-838.
5. Martin W., *et al.* "Neurologic complications of acute and chronic renal disease". *Handbook of Clinical Neurology* 119 (2014): 383-393.
6. Fraser CL and Arieff AI. "Nervous system complications in uremia". *Annals of Internal Medicine*. 2.109 (1988): 143 -153.
7. Alan L. "Neurologic complications of renal disease". *Neurologic Clinics* 3.7 (1973): 617-627.
8. Collado-Seidel V., *et al.* "Clinical and biochemical findings in uremic patients with and without restless legs syndrome". *American Journal of Kidney Diseases* 2. 31 (1998): 324 -328.
9. Winkelman JW., *et al.* "Restless legs syndrome in end-stage renal disease". *American Journal of Kidney Diseases* 3.28 (1996): 372 -378.
10. Halter SK., *et al.* "Carpal Tunnel Syndrome in chronic renal dialysis patients". *Archives of Physical Medicine and Rehabilitation* 62 (1981): 197-201.
11. Albert P., *et al.* "High but stable incidence of subdural haematoma in haemodialysis - a single-centre study". *Nephrology Dialysis Transplantation* 7.25 (2010): 2272-2275.
12. Kwa VIH., *et al.* "Silent intracerebral microhemorrhages in patients with ischemic stroke. Amsterdam Vascular Medicine Group". *Annals of Neurology* 3. 44 (1998): 372-377.
13. Kato H., *et al.* "Silent cerebral microbleeds on T2\*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis". *Stroke* 6.33 (2002): 1536-1540.
14. Roob G., *et al.* "Frequency and location of microbleeds in patients with primary intracerebral hemorrhage". *Stroke* 11. 31 (2000): 2665-2669.
15. Nighoghossian N., *et al.* "Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2\*-weighted brain MRI study". *Stroke* 3. 33 (2002): 735-742.

### Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: [www.actascientific.com/](http://www.actascientific.com/)

Submit Article: [www.actascientific.com/submission.php](http://www.actascientific.com/submission.php)

Email us: [editor@actascientific.com](mailto:editor@actascientific.com)

Contact us: +91 9182824667